Inactive Instrument

Zynerba Pharmaceuticals, Inc.

Equities

ZYNE

US98986X1090

Biotechnology & Medical Research

Zynerba Pharmaceuticals, Inc. Appoints Liza Squires as New Chief Medical Officer

January 04, 2018 at 08:30 am

Zynerba Pharmaceuticals, Inc. announced that Dr. Liza Squires has joined the company team as new Chief Medical Officer reporting to Terri. She brings 25 years of experience in rare and neuropsych disorders to the company.

Latest news about Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.	04-29	CI
Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index	23-10-12	CI
Harmony Biosciences Holdings Completes Acquisition of Zynerba Pharmaceuticals	23-10-11	MT
Harmony Biosciences Holdings, Inc. completed the acquisition of Zynerba Pharmaceuticals, Inc..	23-10-09	CI
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index	23-09-28	CI
Harmony Biosciences Says its Xylophone Acquisition Unit Extends Tender Offer for Zynerba Pharmaceuticals to Oct. 10	23-09-27	MT
North American Morning Briefing : Treasury Yields -2-	23-08-17	DJ
Canaccord Genuity Downgrades Zynerba Pharmaceuticals to Hold From Buy, Adjusts Price Target to $1.11 From $10	23-08-16	MT
North American Morning Briefing : Stock Futures -2-	23-08-16	DJ
HC Wainwright Downgrades Zynerba Pharmaceuticals to Neutral From Buy	23-08-15	MT
Health Care Up on Drug Developments -- Health Care Roundup	23-08-14	DJ
Sector Update: Health Care Stocks Higher Late Afternoon	23-08-14	MT
Sector Update: Health Care Stocks Higher on Monday Afternoon	23-08-14	MT
Top Midday Gainers	23-08-14	MT
Zynerba Pharmaceuticals Shares Soar on Harmony Biosciences Acquisition Deal	23-08-14	MT
Sector Update: Health Care Stocks Edge Higher Premarket Monday	23-08-14	MT
Sector Update: Health Care	23-08-14	MT
Transcript : Harmony Biosciences Holdings, Inc., Zynerba Pharmaceuticals, Inc. - M&A Call	23-08-14
Harmony Biosciences Agrees to Acquire Zynerba Pharmaceuticals	23-08-14	MT
Harmony Biosciences To Acquire Zynerba Pharmaceuticals, Inc.	23-08-14	RE
Zynerba Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Harmony Biosciences Holdings, Inc. entered into a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. ) for $63.7 million.	23-08-13	CI
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from Russell Microcap Value Index	23-06-23	CI
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from Russell 3000E Value Index	23-06-23	CI
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from Russell 3000E Index	23-06-23	CI

Chart Zynerba Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 deletion syndrome (22q). It is focused on using cannabinoids for treating behavioral symptoms of FXS and 22q. The Company is developing Zygel (ZYN002), a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol (THC). It uses a patent protected formulation containing ethanol and propylene glycol as solubilizing agents and Transcutol HP as a permeation enhancer. Zygel is an investigational drug product in development for the potential treatment of behavioral symptoms associated with FXS, 22q, and autism spectrum disorder (ASD).

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+64.23%	62.59B
IQVIA HOLDINGS INC.	-2.31%	41.18B
LONZA GROUP AG	+45.55%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	19.09B
BIO-TECHNE CORPORATION	+7.54%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B
MEDPACE HOLDINGS, INC.	+27.17%	12.05B

Other Biotechnology & Medical Research